Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
3 Months : From Oct 2019 to Jan 2020
- Research, interactive features and charitable opportunity support advancement of care -
Horizon Therapeutics plc (Nasdaq: HZNP) will join the leading voices in the nephrology community this week to inform and build data-based discourse on managing the challenges of gout and kidney disease during the American Society of Nephrology (ASN) Kidney Week, to be held Nov. 5-10 in Washington, D.C.
“While gout has been well understood by its rheumatological manifestations, it is fundamentally a disease caused by the kidney’s inefficiency in eliminating uric acid,” said Paul Peloso, M.D., M.Sc., vice president and therapeutic area head, rheumatology, Horizon. “Growing evidence illustrates the complications caused by gout for those living with chronic kidney disease, particularly those who have received a kidney transplant. We are working to shepherd greater engagement through scientific contributions, awareness building and education to help identify this connection in high risk patients and intervene with confidence.”
Highlights of Horizon’s presence during Kidney Week include poster presentations that depict the etiology of gout among kidney disease patients, particularly among those who have received a transplant. These presentations include:
Assessing the relationship between Gout and Return to Hemodialysis among Renal Transplant Patients
Abstract: FR-PO1171, J. Li
Renal Transplant Complications in Patients with and without Gout
Abstract: FR-PO1170, M. Francis-Sedlak
Evidence of Urate Deposition in the Kidneys in Gout Patients
Abstract: PUB426, B. Marder
Incident gout after renal transplantation in gout-naïve patients: large database analysis
Abstract: PUB329, B. LaMoreaux
Beyond contributions to scientific exchange, Horizon invests in education and awareness efforts to raise the conversation about gout across the community and build greater appreciation for the priorities in patient care. During Kidney Week, Horizon will support advancements in care through interactive education and charitable contributions, to include:
A dynamic, 15-foot interactive nephron machine that demonstrates both the kidney’s retention of uric acid and efficient excretion of allantoin.
Contributions to KidneyCure, the ASN Foundation, from Horizon driven by participant interaction. Horizon will make a donation to KidneyCure of up to $50 for every attendee who interacts with the nephron machine, for a total donation up to $25,000. KidneyCure is an organization that supports the future of the field as talented fellows, young investigators, and nephrology educators challenge and change the evolution of kidney care.
About Uncontrolled Gout
Gout is a chronic, progressive inflammatory form of arthritis that is caused by excess uric acid in the body and needs to be managed aggressively.1 Over time uric acid can build up and form deposits, called tophi, inside the body and joints, which can have harmful effects including causing damage to the underlying bone. Patients with uncontrolled gout continue to have abnormally high levels of uric acid and continued symptoms of gout despite the use of conventional therapies.2
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com, follow us @HorizonNews on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
1 Keuhn B. Chronic Disease Approaches Needed to Curb Gout’s Growing Burden. Journal of the American Medical Association. 2018;319(13):1308-1309.
2 Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-3141.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005235/en/
Senior Vice President, Investor Relations
Executive Director, Investor Relations
U.S. Media Contact:
Associate Director, Public Relations and Social Media
Ireland Media Contact: